the manifold applications for new GSK 3b inhibitors focusing in particular on the program c-Met inhibitor in neurodegenerative diseases. Several drugs have now been thoroughly characterized within this regard. A key compound could be the GSK 3b inhibitor SB 216763 which can be an indolylmaleimide derivative that is normally unique to GSK 3b and functions competitively with ATP. 18 These qualities make SB 216763 an appealing lead structure for new active compounds which might inhibit GSK 3b as well. The synthesized derivates are known in terms of their inhibitory potential on GSK 3b and the result on Wnt signalling in human neural progenitor cells. In this study, we applied the human NPC line ReNcell VM to investigate the natural purpose of the newly synthesized substances. Notably, this cell line can differentiate into neurons, astrocytes, and oligodendrocytes in just a couple of days. 19,20 Beside this, the cell line shows a fast expansion and may be cultured easily which makes it a suitable model system to on neuronal differentiation Gene expression test the impact of GSK 3 inhibitors. Moreover only few reports deal with the differentiation of human neuronal progenitor cells. Following from the previous communication on selected catalytic and stoichiometric activity of low symmetrically tried 4 indolylmaleimides,21 we here explain in more detail chemical and biological data showing the result on Wnt signalling on individual NPCs. As a result, among the new substances showed important biological effects on Wnt signalling within the same range because the identified GSK 3b inhibitor SB 216763. Synthesis of substituted 4 indolylmaleimides Indolylmaleimides 1 7 have now been organized IPA-3 clinical trial by Pd 2/cataCXium A catalyzed carbonylation of 3 bromo 1 methyl 4 maleimide with carbon monoxide in the existence of alcohols or amines at 90 C. 21 Thus, 3 aminocarbonyl 4 indolylmaleimides and novel 3 alkoxycarbonyl were obtained in 7000-rpm yield. Alternatively, new 4 amino 3 indolylmaleimides 8 15 have now been produced in excellent yields via stoichiometric amination of the same 3 bromo 1 methyl 4 maleimides with corresponding amines. Treatment of ReNcell VM with SB 216763, Kenpaullone and indolylmaleimides escalates the volume of total b catenin Initially, we investigated whether or not the application of SB 216763 or Kenpaullone to hNPCs could enhance the degree of total b catenin. Thus, cells were grown under expansion conditions until 70-85 confluence before differentiation was caused. The medications were diluted in differentiation medium at appropriate levels. To determine the sufficient time position for further studies, total cell extracts were prepared over 48 h and the quantity of total b catenin was measured utilizing an ELISA specific for human total b catenin. As expected, the change to differentiation condition triggered a growth of b catenin.